Deear Medical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 27 Year, 26 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.75 M
- Revenue Growth -44.42%
- Profit Growth -89.49%
- Ebitda 48.03%
- Net Worth 2.09%
- Total Assets 31.53%
About Deear Medical
Deear Medical Private Limited (DMPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 January 1998 and has a history of 27 years. Its registered office is in Central Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.75 M.
Raja Singh, Naveen Srivastava, and Ram Singh serve as directors at the Company.
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51109DL1998PTC091942
- Company No.
091942
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jan 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Deear Medical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raja Singh  | Director | 09-Dec-2019 | Current |
| Naveen Srivastava | Director | 09-Dec-2019 | Current |
| Ram Singh | Director | 28-Jan-1998 | Current |
Financial Performance of Deear Medical.
Deear Medical Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 44.42% decrease. The company also saw a substantial fall in profitability, with a 89.49% decrease in profit. The company's net worth moved up by a moderate rise of 2.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deear Medical?
In 2018, Deear Medical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.75 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of Patiala : 0.20 Cr
- Others : 0.10 Cr
- Syndicate Bank : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jul 2023 | Others | ₹1.00 M | Open |
| 15 Nov 2011 | State Bank Of Patiala | ₹2.00 M | Open |
| 16 Jan 2006 | Syndicate Bank | ₹0.75 M | Open |
How Many Employees Work at Deear Medical?
Unlock and access historical data on people associated with Deear Medical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deear Medical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deear Medical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
